Mobile clinic brings HIV treatment to the streets: Same-Day start could transform care for the excluded

NCT ID NCT05405751

Completed Disease control Sponsor: Fundacion SEIMC-GESIDA Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests a new way to help vulnerable people with HIV get diagnosed and start treatment right away using a mobile screening unit. Participants receive the once-daily pill Biktarvy on the same day they are enrolled. The goal is to see if this approach helps them stay in care and keep the virus under control over 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy)
What this could lead to: If effective, this approach could help hard-to-reach groups get HIV under control quickly and stay in care, reducing transmission and improving health outcomes.
What could go wrong: This is a small, single-group study without a comparison group, so results may not apply broadly. Side effects from the medication or challenges in keeping participants engaged could limit success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

H. Infanta Leonor

Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.